John B. Henneman
Lead Independent DirectorMr. John B. Henneman, III, also known as Jack, J.D., has been Lead Director of R1 RCM Inc. since February 7, 2022. He serves as Independent Director at Orthofix Medical Inc. since January 5, 2023. He is an Independent Director at Aprea Therapeutics, Inc. from August 2019 and had been its Lead Independent Director until November 2023. He serves as Lead Independent Director at Aprea Therapeutics AB since September 2020. He serves as Independent Director at Anika Therapeutics, Inc. since August 2019 and also served as Lead Independent Director since September 2020 until February 24, 2024 and served as its Independent Chair of the Board since February 24, 2024 until February 01, 2026 and serves as Lead Independent Director since February 01, 2026. He served as a Senior Advisor at Prettybrook Partners LLC since May 2018 till 2025 and a consultant to SparkMed Advisors LLC since January 2019. Mr. Henneman served as Member of Advisory Board at TransCode Therapeutics, Inc until June 2025. Mr. Henneman serves as a Director at Alafair Biosciences, Inc. since January 2015. He has been Director of Aprea Therapeutics AB since August 2019. He served as a Secretary at NewLink Genetics Corporation from October 01, 2014 to November 2018 and its Chief Administrative Officer from July 31, 2018 to November 2018. Mr. Henneman served as the Executive Vice President & Chief Financial Officer of NewLink Genetics Corporation since October 01, 2014 until July 31, 2018 and previously served as its Chief Administrative Officer since 2014 and Executive Vice President. Mr. Henneman has many years of combined financial and operational management experience in the life sciences industry. He served as Corporate Vice President at Integra LifeSciences Holdings Corporation since May 2, 2014. He has extensive experience in the areas of finance, financial accounting, business transactions, law and mergers and acquisitions. Mr. Henneman served as the Chief Financial Officer of Integra LifeSciences Holdings Corporation from May 13, 2008 to May 2, 2014 and its Corporate Vice President of Finance and Administration from December 01, 2012 to May 2, 2014. He was responsible for the law department, regulatory affairs and quality systems, business development, human resources, information management and investor relations. Mr. Henneman served as an Executive Vice President of Finance & Administration and Executive Vice President at Integra LifeSciences Holdings Corporation and served as its Acting Chief Financial Officer from September 7, 2007 to May 13, 2008, Chief Financial Officer since September 7, 2007, General Counsel since joining Integra LifeSciences in September 1998 and held that role up to 2014, Chief Administrative Officer from September 2000 to May 13, 2008 and Senior Vice President & Secretary from September 2000 to February 2003. He was responsible at various times for Integra's business development, regulatory affairs, quality systems, clinical affairs, human resources, information systems and legal affairs functions and the management of Integra's surgical instruments business. Mr. Henneman served Integra LifeSciences in various capacities between 1998 and 2014. He served in the additional capacity of interim Co-Chief Executive Officer of Neuromedical Systems from June 1997 to November 1997 and served as its Executive Vice President of US Operations and Chief Legal Officer from December 1997 to August 1998. From 1994 to June 1997, he served as Vice President of Corporate Development, General Counsel and Secretary at Neuromedical System. He serves on the Advisory Board of Transcode Therapeutics, Inc. He joined Neuromedical Systems in February 1994. For more than seven years prior to joining Neuromedical Systems, he practiced law with the Chicago office of Latham & Watkins. He was Independent Director of SeaSpine Holdings Corporation July 1, 2015 until January 2023 and is Independent Director of R1 RCM Inc. (Former Name: Accretive Health, Inc.) since February 16, 2016. Mr. Henneman received A.B. degree in Politics from Princeton University from 1979 to 1983 and a J.D. in Law from the University of Michigan Law School from 1983 to 1986.
Positions
- Company NameAnika Therapeutics, Inc.Stock CodeANIKPositionLead Independent DirectorColleagues
- CRCheryl Renee BlanchardExecutive Chair
- SDStephen D. GriffinPresident, Principal Financial Officer, CEO & Director
- IWIan W. McLeodSenior VP, Chief Accounting Officer & Treasurer
- MHMatthew HallExecutive Director of Corporate Development & Investor Relations
- LFLisa FunicielloVP & Chief Human Resources Officer
- SOStephen O. RichardIndependent Director
- JBJohn B. HennemanLead Independent Director
- SLSheryl L. ConleyIndependent Director
- Company NameOrthofix Medical Inc.Stock CodeOFIXPositionIndependent DirectorColleagues
- MCMassimo CalafiorePresident, CEO & Director
- MMMichael M. FineganIndependent Chair of the Board
- JBJulie B. AndrewsChief Financial Officer
- AMAviva McPherronPresident of Global Operations & Quality
- JAJ. Andres CedronChief Legal Officer & Corporate Secretary
- PFPatrick FisherPresident of Global Biologics & Limb Reconstruction
- JMJason Marshall HannonIndependent Director
- WCWayne C. BurrisIndependent Director
- Company NameAprea Therapeutics, Inc.Stock CodeAPREPositionIndependent DirectorColleagues
- OGOren GiladCo-Founder, CEO, President & Director
- RPRichard PetersIndependent Chairperson of the Board
- JPJohn P. HamillSenior VP, CFO, Principal Accounting Officer & Secretary
- LBLars B. AbrahmsenSenior VP & Chief Scientific Officer
- BWBrian WileySenior Vice President of Corporate Development & Strategy
- MAMichel AfarganHead of Pharmacology Development
- MJMichael J. GrissingerIndependent Director
- JBJohn B. HennemanIndependent Director
- RPRifat PamukcuIndependent Director
